Varenicline for Tobacco Dependence
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
A 57-year-old man presents to his primary care provider because he would like to quit smoking. A trial of varenicline, a partial agonist of the nicotinic acetylcholine receptor that has been shown to increase rates of smoking abstinence as compared with placebo, is recommended. In light of reports of neuropsychiatric side effects, including suicidal behavior, patients treated with varenicline should be closely monitored for behavioral symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Actual causes of death in the United States
McGinnis, J. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180077038 · Cited by 5,480
Actual Causes of Death in the United States, 2000
Mokdad, A. H. (2004) · JAMA · doi:10.1001/jama.291.10.1238 · Cited by 5,211
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Nicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis
Wu, P., Wilson, K., Dimoulas, P., & Mills, E. J. (2006) · BMC Public Health · doi:10.1186/1471-2458-6-300 · Cited by 484
Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal
S. Watkins, G. F. K. (2000) · Nicotine & Tobacco Research · doi:10.1080/14622200050011277 · Cited by 424
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Rigotti, N. A., Pipe, A. L., Benowitz, N. L., Arteaga, C., Garza, D., & Tonstad, S. (2010) · Circulation · doi:10.1161/circulationaha.109.869008 · Cited by 369
Schroeder, S. A., & Morris, C. D. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103701 · Cited by 349
The treatment of cocaine use disorder
Kampman, K. M. (2019) · Science Advances · doi:10.1126/sciadv.aax1532 · Cited by 250
Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200
“As it acts on the central nervous system and its effects include the stimulation of dopamine release, it is possible that it may have an impact on mood and suicide risk.”
Background
Metadata
- Authors
- Hays, J. T., & Ebbert, J. O.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-11-06
- Volume
- 359
- Issue
- 19
- Pages
- 2018-2024
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2028767159
- Cited by
- 129
- References
- 14
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varenicline for Tobacco Dependence. https://app.cochat.ai/papers/10.1056/nejmct0800146
- The paper
- Hays, J. T., & Ebbert, J. O. (2008). Varenicline for Tobacco Dependence. New England Journal of Medicine. https://doi.org/10.1056/nejmct0800146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.